13F Data
13F filer · CIK 2050194

Spruce Street Capital LP

NEW YORK, NY · filing since Q4 2025 · last filing Aug 13, 2026
Reported value
$509.7M
+$93.7M vs prior
Positions
30
New / sold out
5 / 3
Added / reduced
8 / 1
Turnover
9.8%
buys $62.6M · sells $45.3M
Top-10 weight
70.2%

Biggest buys vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
NewINFLARX NV+5,352,198–+$12.0M
AddedALKERMES PLC+225,884+71.0%+$11.8M
AddedKINIKSA PHARMACEUTICALS INTL+157,007+20.6%+$10.0M
NewRESEARCH ALLIANCE CORP III+500,000–+$5.3M
NewZAI LAB LTD+279,110–+$5.3M
NewACHIEVE LIFE SCIENCE INC+736,637–+$4.8M
AddedPERSPECTIVE THERAPEUTICS INC+1,066,824+40.6%+$3.6M
AddedVAXCYTE INC+60,338+24.6%+$3.5M
AddedENANTA PHARMACEUTICALS INC+156,133+16.7%+$2.3M
NewJATT II ACQUISITION CORP+160,000–+$1.8M
3 more rows. Subscribe for $29/month to see every row, download the data and use the API.

Biggest sells vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
Sold outCENTESSA PHARMACEUTICALS-489,849-100.0%$-19.5M
Sold outKALVISTA PHARMACEUTICALS-897,681-100.0%$-18.1M
Sold outMAZE THERAPEUTICS INC-200,000-100.0%$-6.0M
ReducedDIANTHUS THERAPEUTICS INC-18,458-4.9%$-1.8M

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2025: $302.7MQ1 2026: $415.9MQ2 2026: $509.7M
Q4 2025Q2 2026

Holdings · Q2 2026

#SecuritySharesValueWeight
1KINIKSA PHARMACEUTICALS INTLORD SHS CL A918,070$58.7M11.52%
2RELAY THERAPEUTICS INCCOM2,984,125$55.8M10.95%
3LB PHARMACEUTICALS INCCOM SHS1,376,159$44.7M8.76%
4RELMADA THERAPEUTICS INCCOM6,391,328$44.2M8.68%
5ALTO NEUROSCIENCE INCCOM SHS1,353,047$35.7M7.01%
6DIANTHUS THERAPEUTICS INCCOM354,816$34.6M6.79%
7ALKERMES PLCSHS543,876$28.5M5.59%
8SAVARA INCCOM3,452,576$21.3M4.17%
9VAXCYTE INCCOM306,047$17.8M3.49%
10ENLIVEN THERAPEUTICS INCCOM329,006$16.7M3.28%
20 more rows. Subscribe for $29/month to see every row, download the data and use the API.